SRRK Stock Forecast & Price Target

Scholar Rock Holding is positioned to benefit from the first FDA approval of ISEMBYLD, which gives it a wholly owned, commercial-stage asset in SMA and validates apitegromab’s clinically meaningful 2.2-point HFMSE improvement in SAPPHIRE. The label appears broader than expected, with no restrictions by subtype, ambulatory status, baseline HFMSE, or prior therapy duration, while KOL feedback suggests fracture and reproductive warnings are unlikely to materially limit prescribing given the high unmet need and existing SMA fracture background risk. Financially, management expects about $310K in annual net revenue per typical patient at $11,659 per 150-mg vial, supporting a modeled roughly $2.4B global peak opportunity and upside from future expansion into FSHD and SRK-439.

Scholar Rock Holding is a high-risk biotech with a limited commercial moat because payer duration risk could make Isembyld reimbursement less favorable than SMN modifiers, given it does not preserve motor neurons and may face tougher insurer scrutiny. The SAPPHIRE motor-scale gains were described as being on the smaller end of significance, with only about a 2-point improvement versus the burden of monthly IV infusions, which may limit adoption among older, more stable patients. The bearish case is further reinforced by potential real-world safety issues, a negative EC regulatory decision for European sales, and pricing reform that could pressure rare-disease reimbursement despite the company’s clinical-stage pipeline.